Title: Bortezomib: Proteasome Inhibition as a Novel Mechanism of Cancer Therapy-Implications for Hematological Malignancies
VOLUME: 4 ISSUE: 2
Author(s):Joesph Mikhael and Hong Chang
Affiliation:Department of Laboratory Hematology, 200 Elizabeth St., 11E-413, Toronto General Hospital,University Health Network, Toronto, M5G 2C4, Canada.
Keywords:Proteasome inhibitor, Bortezomib, Multiple myeloma, Clinical trial, Cancer
Abstract: The proteasome is a multicatalytic proteinase complex that is responsible for protein turnover through the ubiquitin-proteasome pathway. Bortezomib is the first drug to act as a proteasome inhibitor, and has yielded impressive anticancer effects in phase III trials in multiple myeloma. Its role in other hematological malignancies is being evaluated. Proteasome inhibition, therefore, represents a novel mechanism for anticancer therapy.
